On Aug. 12, 2021, Rentschler Biopharma announced that it has broken ground at its new production site, adjacent to its existing Milford, Mass., site where it will build the Rentschler Biopharma Manufacturing Center US, a new facility that will add 22,000 ft2 of manufacturing cleanroom space and house four new 2000-L single-use bioreactors. The company expects the RBMC US to be operational in late 2023.
The facility is designed with upstream ballroom processing-size space for production flexibility and downstream processing suites equipped with buffer storage and preparation space.
